These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 35001356)

  • 21. Gene networks in neurodegenerative disorders.
    Recabarren D; Alarcón M
    Life Sci; 2017 Aug; 183():83-97. PubMed ID: 28623007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Links between COVID-19 and Parkinson's disease/Alzheimer's disease: reciprocal impacts, medical care strategies and underlying mechanisms.
    Huang P; Zhang LY; Tan YY; Chen SD
    Transl Neurodegener; 2023 Jan; 12(1):5. PubMed ID: 36717892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Evidence in Epigenomics and Proteomics Biomarkers for Early and Minimally Invasive Diagnosis of Alzheimer's and Parkinson's Diseases.
    Mayo S; Benito-León J; Peña-Bautista C; Baquero M; Cháfer-Pericás C
    Curr Neuropharmacol; 2021; 19(8):1273-1303. PubMed ID: 33357195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deciphering the function and regulation of microRNAs in Alzheimer's disease and Parkinson's disease.
    Qiu L; Zhang W; Tan EK; Zeng L
    ACS Chem Neurosci; 2014 Oct; 5(10):884-94. PubMed ID: 25210999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetics in Parkinson's and Alzheimer's diseases.
    Marques S; Outeiro TF
    Subcell Biochem; 2013; 61():507-25. PubMed ID: 23150265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of microRNAs in neurodegeneration induced by environmental neurotoxicants and aging.
    Singh T; Yadav S
    Ageing Res Rev; 2020 Jul; 60():101068. PubMed ID: 32283224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific Signatures of Serum miRNAs as Potential Biomarkers to Discriminate Clinically Similar Neurodegenerative and Vascular-Related Diseases.
    Barbagallo C; Mostile G; Baglieri G; Giunta F; Luca A; Raciti L; Zappia M; Purrello M; Ragusa M; Nicoletti A
    Cell Mol Neurobiol; 2020 May; 40(4):531-546. PubMed ID: 31691877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies.
    Ciceri F; Rotllant D; Maes T
    Curr Pharm Des; 2017; 23(5):839-857. PubMed ID: 28120717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy Bodies or Alzheimer's disease.
    Atkinson A; Singleton AB; Steward A; Ince PG; Perry RH; McKeith IG; Fairbairn AF; Edwardson JA; Daly AK; Morris CM
    Pharmacogenetics; 1999 Feb; 9(1):31-5. PubMed ID: 10208640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current Research on Pro-drug Therapies for Parkinson's and Alzheimer's Disease.
    Huo C; Wu L; Jiang Z; Yang J; Wang Z; Li Y; Qian S
    Med Chem; 2022; 18(6):655-666. PubMed ID: 34847848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging pathways to neurodegeneration: Dissecting the critical molecular mechanisms in Alzheimer's disease, Parkinson's disease.
    Tan SH; Karri V; Tay NWR; Chang KH; Ah HY; Ng PQ; Ho HS; Keh HW; Candasamy M
    Biomed Pharmacother; 2019 Mar; 111():765-777. PubMed ID: 30612001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shared mechanisms of neurodegeneration in Alzheimer's disease and Parkinson's disease.
    Xie A; Gao J; Xu L; Meng D
    Biomed Res Int; 2014; 2014():648740. PubMed ID: 24900975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The apolipoprotein E epsilon 4 allele in Parkinson's disease with Alzheimer lesions.
    Egensperger R; Bancher C; Kösel S; Jellinger K; Mehraein P; Graeber MB
    Biochem Biophys Res Commun; 1996 Jul; 224(2):484-6. PubMed ID: 8702415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics.
    Pan Y; Nicolazzo JA
    Adv Drug Deliv Rev; 2018 Oct; 135():62-74. PubMed ID: 29665383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Orchestration of a blood-derived and ADARB1-centred network in Alzheimer's and Parkinson's disease.
    Song Z; Ding Q; Yang Y
    Cell Signal; 2023 Oct; 110():110845. PubMed ID: 37544632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olfaction deterioration in cognitive disorders in the elderly.
    Ottaviano G; Frasson G; Nardello E; Martini A
    Aging Clin Exp Res; 2016 Feb; 28(1):37-45. PubMed ID: 26003671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olfaction as an early marker of Parkinson's disease and Alzheimer's disease.
    Walker IM; Fullard ME; Morley JF; Duda JE
    Handb Clin Neurol; 2021; 182():317-329. PubMed ID: 34266602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The contribution of altered neuronal autophagy to neurodegeneration.
    Filippone A; Esposito E; Mannino D; Lyssenko N; Praticò D
    Pharmacol Ther; 2022 Oct; 238():108178. PubMed ID: 35351465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer's and Parkinson's Diseases.
    Jagaran K; Singh M
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitochondrial DNA in pathogenesis of Alzheimer's and Parkinson's diseases.
    Maruszak A; Gaweda-Walerych K; Sołtyszewski I; Zekanowski C
    Acta Neurobiol Exp (Wars); 2006; 66(2):153-76. PubMed ID: 16886726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.